End-of-day quote
Shenzhen S.E.
03:30:00 31/05/2024 am IST
5-day change
1st Jan Change
3.62
CNY
+0.28%
+0.28%
-14.62%
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2020
August 24, 2020 at 04:46 pm IST
Tianjin Chase Sun Pharmaceutical Co.,Ltd announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 2,782.174 million compared to CNY 2,287.734 million a year ago. Operating income was CNY 345.806 million compared to CNY 418.889 million a year ago. Net income was CNY 343.775 million compared to CNY 350.281 million a year ago. Basic earnings per share from continuing operations was CNY 0.11 compared to CNY 0.12 a year ago.
Tianjin Chase Sun Pharmaceutical's 2023 Profit Slides 15% on Weak Revenue
01/03
MT
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
29/02
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
25/23/25
CI
Tianjin Chase Sun Pharma’s Muscle Relaxant Passes Drug Consistency Test
22/23/22
MT
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
29/23/29
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
27/23/27
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
27/23/27
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
24/22/24
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
30/22/30
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
28/22/28
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
28/22/28
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
28/21/28
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
27/21/27
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
27/21/27
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
30/21/30
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd cancelled the acquisition of additional 25% stake in Hubei Enoray Biopharmaceutical Co., Ltd. from Hubei Wurui Biotechnology Co., Ltd. for CNY 60 million.
19/21/19
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces the Election of Li Li as an Independent Director
20/20/20
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
29/20/29
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd(XSEC:300026) added to S&P Global BMI Index
21/20/21
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2020
24/20/24
CI
Starpharma Announce Signs New Research Partnership with Tianjin Chase Sun Pharmaceutical Co., Ltd
17/20/17
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020
28/20/28
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2019
27/20/27
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd intends to acquire additional 25% stake in Hubei Enoray Biopharmaceutical Co., Ltd. from Hubei Wurui Biotechnology Co., Ltd. for CNY 60 million.
22/20/22
CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2019
28/19/28
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Tianjin Chase Sun Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Company's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The Company also provides medical apparatus and instrument. The Company distributes its products in domestic market and to overseas markets.
More about the company
Last Close Price
3.62
CNY
Average target price
4
CNY
Spread / Average Target
+10.50%
Consensus
1st Jan change
Capi.
-14.62% 150.16Cr +37.29% 602.09Cr -21.28% 418.94Cr +4.52% 325.49Cr -18.16% 287.36Cr -7.70% 237.49Cr +41.50% 188.52Cr -4.05% 157.98Cr -15.56% 154.04Cr +40.06% 144.59Cr
Alternative Medicine
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1